CAEBi to present ADAPTED at Alzheimer Europe Conference 2019

October 15, 2019

ADAPTED project partner Maria Sáez is attending the 29th Alzheimer Europe Conference  on Thursday 24th October. Her presentation will be part of the first NEURONET annual networking and communication event which aims to showcase Innovative Medicine Initiative (IMI) projects that work in the area of neurodegeneration research. 

 

Maria is one of the founders of CAEBi, based in Seville and is the leader of the ADAPTED Bioinformatics team, who are collecting, harmonising and mining the data generated from the project. Her achievements within the project include the implementation of a data storage and analysis platform which currently has information for more than 70,000 human samples from diverse omics, and pipelines for analysing and combining multi-omic data. You can find out more about Maria's work on ADAPTED and her hopes for the future of treatment of Alzheimer's disease in our researcher profile here!

 

She will be presenting ADAPTED alongside scientists and researchers from other projects within IMI's neurodegeneration portfolio at this event organised by NEURONET. The event will present a series of four parallel sessions to showcase the state of the art in European neurodegeneration research. Download the full conference brochure here.

 

Taking place within the 29th Alzheimer Europe Conference in The Hague, this event is a great opportunity for dementia experts to meet and share knowledge and experiences. The conference welcomes not only researchers, but people with dementia, their families, volunteer and staff from Alzheimer associations together with policy makers, health and social care professionals, researchers and industry representatives from all over Europe and beyond. 

 

For more information or to register to the conference go to the Alzheimer Europe website. 

 

 

 

 

 

Please reload

Other Items
Please reload

©2018 ADAPTED

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No 115975. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations